Published in Oncotarget on April 01, 2012
Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection. J Thorac Cardiovasc Surg (2015) 1.48
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus (2012) 1.05
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol (2013) 1.04
Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One (2013) 1.04
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther (2013) 0.92
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
A preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer. Ann Transl Med (2015) 0.91
Farletuzumab in lung cancer. Lung Cancer (2013) 0.88
Targeting folate receptor alpha for cancer treatment. Oncotarget (2016) 0.84
A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application. Cell Chem Biol (2016) 0.84
A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget (2015) 0.84
Comparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging. Int J Mol Imaging (2015) 0.82
Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha. Biomark Insights (2016) 0.82
Acetylation of MAT IIα represses tumour cell growth and is decreased in human hepatocellular cancer. Nat Commun (2015) 0.81
The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget (2013) 0.80
Expression of high affinity folate receptor in breast cancer brain metastasis. Oncotarget (2015) 0.79
A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther (2015) 0.79
Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget (2016) 0.78
Intraoperative molecular imaging to identify lung adenocarcinomas. J Thorac Dis (2016) 0.77
Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates. Mol Pharmacol (2016) 0.77
Detection of circulating tumor cells in non-small cell lung cancer. J Thorac Dis (2016) 0.77
Folate receptor alpha: a new tool in the diagnosis and treatment of lung cancer. Oncotarget (2012) 0.77
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer. Oncotarget (2015) 0.77
Investigating CTCs in NSCLC-a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer. J Thorac Dis (2016) 0.77
Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease. Biomark Insights (2014) 0.77
Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia. Int J Clin Exp Pathol (2015) 0.77
Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget (2016) 0.77
Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. Oncotarget (2016) 0.76
ATPase inhibitory factor 1 expression is an independent prognostic factor in non-small cell lung cancer. Am J Cancer Res (2016) 0.76
MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. Oncotarget (2016) 0.75
Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer. J Cancer (2017) 0.75
Profile of farletuzumab and its potential in the treatment of solid tumors. Onco Targets Ther (2016) 0.75
Multi-Modal Imaging in a Mouse Model of Orthotopic Lung Cancer. PLoS One (2016) 0.75
Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry. BBA Clin (2017) 0.75
Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential. Oncotarget (2017) 0.75
Rapid and Selective Determination of Folate Receptor α with Sensitive Resonance Rayleigh Scattering Signal. Int J Anal Chem (2017) 0.75
One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy. Oncotarget (2017) 0.75
Folate receptor-targeted ultrasonic PFOB nanoparticles: Synthesis, characterization and application in tumor-targeted imaging. Int J Mol Med (2017) 0.75
Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. Mol Pharm (2016) 0.75
Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment. Top Curr Chem (J) (2017) 0.75
ImmunoPET imaging of tissue factor expression in pancreatic cancer with (89)Zr-Df-ALT-836. J Control Release (2017) 0.75
Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. Sci Rep (2017) 0.75
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res (1992) 3.66
Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst (2004) 3.51
Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev (2004) 2.56
The biological chemistry of folate receptors. Blood (1992) 2.27
Overexpression of folate binding protein in ovarian cancers. Int J Cancer (1997) 2.13
Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol (2009) 1.97
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol (2009) 1.74
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res (1992) 1.38
Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer (1998) 1.36
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol (2006) 1.31
Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol (2008) 1.30
The labile folate of milk. Am J Clin Nutr (1966) 1.30
Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol (2009) 1.29
Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol (2009) 1.28
Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther (2010) 1.21
Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol (2008) 1.14
Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood (1999) 1.13
New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl (1994) 1.11
Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 1.06
EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs (2010) 1.03
Role of folate receptor genes in reproduction and related cancers. Front Biosci (2006) 1.02
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One (2009) 0.96
Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int J Cancer (1991) 0.93
A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybridoma (Larchmt) (2007) 0.89
Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. Am J Physiol (1987) 0.85
Renal folate absorption and the kidney folate binding protein. II. Microinfusion studies. Am J Physiol (1987) 0.85
Inhibition of α folate receptor resulting in a reversal of taxol resistance in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg (2011) 0.83
Evolving options in the management of esophageal perforation. Ann Thorac Surg (2004) 4.12
Point: developing a curriculum in clinical pathology. Clin Chem (2006) 2.92
A novel approach to eliminate cardiac perforation in the nuss procedure. Ann Thorac Surg (2013) 2.28
Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol (2012) 2.14
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res (2005) 1.86
Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res (2009) 1.86
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Current management of esophageal leiomyoma. J Am Coll Surg (2004) 1.82
Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene (2005) 1.78
A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med (2013) 1.69
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Sleeve lobectomy: current indications and future directions. Ann Thorac Cardiovasc Surg (2010) 1.58
Cellular adaptive inflammation mediates airway granulation in a murine model of subglottic stenosis. Otolaryngol Head Neck Surg (2011) 1.58
Complete resection of pulmonary inflammatory pseudotumors has excellent long-term prognosis. J Thorac Cardiovasc Surg (2008) 1.56
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
CCL2 blockade augments cancer immunotherapy. Cancer Res (2009) 1.48
Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration. Anal Chem (2010) 1.47
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol (2003) 1.41
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res (2006) 1.40
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A (2012) 1.40
Pulse steroid therapy inhibits murine subglottic granulation. Otolaryngol Head Neck Surg (2012) 1.38
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res (2005) 1.37
Giant bullous lung disease: evaluation, selection, techniques, and outcomes. Chest Surg Clin N Am (2003) 1.37
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res (2008) 1.35
Gene induction during differentiation of human pulmonary type II cells in vitro. Am J Respir Cell Mol Biol (2006) 1.35
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer. PLoS One (2010) 1.31
Intraoperative near-infrared imaging of surgical wounds after tumor resections can detect residual disease. Clin Cancer Res (2012) 1.30
Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol (2009) 1.29
Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res (2005) 1.26
Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res (2011) 1.24
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther (2010) 1.23
A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med (2015) 1.22
A paradigm shift for sternal reconstruction using a novel titanium rib bridge system following oncological resections. Eur J Cardiothorac Surg (2012) 1.20
Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy (2013) 1.19
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res (2005) 1.19
Advances in diagnostic bronchoscopy. Am J Respir Crit Care Med (2010) 1.18
Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer (2013) 1.16
Increased proteolysis, myosin depletion, and atrophic AKT-FOXO signaling in human diaphragm disuse. Am J Respir Crit Care Med (2010) 1.16
Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study. Chest (2015) 1.16
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther (2010) 1.15
Local and systemic recurrence is the Achilles heel of cancer surgery. Ann Surg Oncol (2011) 1.15
Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther (2009) 1.14
MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One (2012) 1.13
Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. Chest (2015) 1.11
Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med (2012) 1.10
A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma. Clin Cancer Res (2007) 1.10
Dietary flaxseed supplementation ameliorates inflammation and oxidative tissue damage in experimental models of acute lung injury in mice. J Nutr (2006) 1.10
Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury. Cancer Biol Ther (2009) 1.08
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med (2011) 1.07
Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 1.06
Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg (2004) 1.05
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus (2012) 1.05
Consensus definitions to promote an evidence-based approach to management of the pleural space. A collaborative proposal by ESTS, AATS, STS, and GTSC. Eur J Cardiothorac Surg (2011) 1.05
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med (2009) 1.02
Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity. Nat Med (2013) 1.02
Evidence-based suggestions for management of air leaks. Thorac Surg Clin (2010) 1.01
A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biol Ther (2012) 1.00
Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol (2013) 0.98
Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS. Bioanalysis (2011) 0.97
Peripheral immune cell gene expression predicts survival of patients with non-small cell lung cancer. PLoS One (2012) 0.96
An Official American Thoracic Society/American College of Chest Physicians Policy Statement: Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in Clinical Practice. Am J Respir Crit Care Med (2015) 0.96
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia (2012) 0.96
Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. Mol Cell Biochem (2012) 0.95
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol (2011) 0.94
Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol (2005) 0.94
Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology (2013) 0.94
Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol (2012) 0.94
Benign pneumatosis intestinalis in the setting of celiac disease. J Gastrointest Surg (2006) 0.94
Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity. Int J Cancer (2014) 0.94
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem (2011) 0.94
Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer (2013) 0.93
Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev (2012) 0.93
8-Oxo-2'-deoxyguanosine as a biomarker of tobacco-smoking-induced oxidative stress. Free Radic Biol Med (2012) 0.92
Liquid chromatography/mass spectrometry of pre-ionized Girard P derivatives for quantifying estrone and its metabolites in serum from postmenopausal women. Rapid Commun Mass Spectrom (2011) 0.92
Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer (2011) 0.91
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
Adjuvant radiotherapy for completely resected stage 2 thymoma. Cancer (2011) 0.90
Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest (2013) 0.90
A population-based study of lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations. Cancer (2005) 0.88
Pilot randomized study comparing two techniques of airway anaesthesia during curvilinear probe endobronchial ultrasound bronchoscopy (CP-EBUS). Respirology (2011) 0.87
Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg Oncol (2013) 0.87
Urinary volatile compounds as biomarkers for lung cancer. Biosci Biotechnol Biochem (2012) 0.87
Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. Anal Chem (2013) 0.87
Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy. Microvasc Res (2011) 0.86
Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract (2012) 0.85